Evaxion announces executive management changes to strengthen the ai-strategy

Copenhagen, denmark, aug. 29, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today announced:

EVAX Ratings Summary

EVAX Quant Ranking